阿托品治疗肥厚性幽门狭窄的研究进展  

Research therapeutic advances of atropine for hypertrophic pyloric stenosis

作　　者：周燕 樊剑锋 程明 Zhou Yan;Fan Jianfeng;Cheng Ming(Department of Neonatal Surgery,Affiliated Wuxi People's Hospital,Nanjing Medical University,Wuxi 214023,China)

机构地区：[1]南京医科大学附属无锡人民医院新生儿外科,无锡214023

出　　处：《临床小儿外科杂志》2024年第5期485-488,共4页Journal of Clinical Pediatric Surgery

基　　金：无锡市科学技术局项目(N20192040)

摘　　要：肥厚性幽门狭窄(hypertrophic pyloric stenosis,HPS)是由于幽门肌增生肥厚引起的胃出口梗阻性疾病,其发病机制尚未完全清楚,可能继发于幽门肌的持续性痉挛或失弛缓。阿托品作为M胆碱能受体阻断剂,能解除幽门肌痉挛,被用于HPS的保守治疗。阿托品治疗HPS,最早采用口服给药,近年来又采用静脉注射给药。阿托品静脉注射治疗HPS,采取序贯用药的方式疗效较好,是HPS保守治疗的新方法。本文就阿托品治疗HPS的新进展进行综述。Hypertrophic pyloric stenosis(HPS)is a common condition caused by gastric outlet obstruction.Its pathogenesis has remained elusive.Hypertrophy of pylorus may be secondary to persistent spasm of pyloric muscle.As a M-choline receptor blocker,atropine treats HPS effectively through relieving gastrointestinal smooth muscle spasm.With recent popularization of a new regimen of atropine,the conservative treatment of HPS has attracted greater attention.This review summarized the latest researches in atropine dosing for HPS to provide rationales for its clinical applications and researches.

关 键 词：肥厚性幽门狭窄 阿托品 

分 类 号：R726.5[医药卫生—儿科]